Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Lantheus Holdings Inc (Lantheus) is a radiopharmaceutical company that specializes in the development and distribution of precision diagnostic and therapeutic products. Its products include piflufolastat F 18 injection, injectable suspension and florbetaben F18 injection. The company’s pipeline products include LNTH-2401 which treats Metastatic prostate cancer; LNTH-2501 and EVG-001 for Neuroendocrine tumors; LNTH-1363S which targets Tumor and fibrosis assessment; LNTH-2503 which treats Small cell lung cancer; LNTH-2505 for Glioblastoma; LNTH-2507 which targets Pancreatic ductal adenocarcinoma; LNTH-2509 for Lobular breast cancer; MK-6240, NAV-4694 and LNTH-2620 or PI-2620 which targets Alzheimer’s disease; among others. It has operations in Canada, Sweden, Ireland, the UK and the US. Lantheus is headquartered in Bedford, Massachusetts, the US.
Headquarters
United States of America
Address
South Building, 201 Burlington Road, Massachusetts, 01730
Website
www.lantheus.com
Telephone
1 800 3622668
No of Employees
1,193
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LNTH (NASD)
Revenue (2024)
$1.5B
0.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-25.2%
(2024 vs 2023)
Market Cap*
$6.5B
Net Profit Margin (2024)
XYZ
-25.6%
(2024 vs 2023)
* As of and is in US$
Lantheus Holdings Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Piflufolastat F 18 Injection | NEUROLITE |
| Injectable Suspension | Cardiolite |
| Florbetaben F18 Injection | Pylarify |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In August, the company secured approval from the U.S. Food and Drug Administration for TAUKLARIFY (florquinitau F 18 injection). |
| 2026 | Contracts/Agreements | In August, the company entered into an agreement to sell its entire stake to Curium US Holdings LLC. |
| 2026 | Regulatory Approval | In March, the company received approval from the US Food and Drug Administration for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent1 version of LUTATHERA (lutetium Lu 177 dotatate). |
Competitor Comparison
| Key Parameters | Lantheus Holdings Inc | Cardinal Health Inc | GE HealthCare Technologies Inc | Blue Earth Diagnostics Inc | Jubilant Pharma Holdings Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | - | Dublin | Chicago | Middlesex | Yardley |
| State/Province | Massachusetts | Ohio | Illinois | New Jersey | Pennsylvania |
| No. of Employees | 1,193 | 63,900 | 54,000 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mary Anne Heino | Chairman; Chief Executive Officer - Interim | Executive Board | 2015 | 66 |
| Robert J. Marshall | Chief Financial Officer; Treasurer | Senior Management | 2018 | 59 |
| Kim Brown | Chief Accounting Officer | Senior Management | 2024 | - |
| Cheryl Ball | Chief Strategy Officer; Head - Corporate Development | Senior Management | 2019 | 59 |
| Lee Anne Howe | Chief Information Officer | Senior Management | 2016 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer